PB2019: EFFICACY AND SAFETY OF IXAZOMIB PLUS LENALIDOMIDE AND DEXAMETHASONE FOLLOWING INJECTABLE PROTEASOME INHIBITOR-BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

• M. Sasaki,
• K. Suzuki,
• Y. Abe,
• S. Ito,
• K. Nishiwaki,
• H. Handa,
• T. Chou,
• J. Soeda,
• I. Mori,
• T. Shinozaki,
• N. Takezako

Affiliations

M. Sasaki

1 Division of Hematology, Department of Internal Medicine, Juntendo University School of Medicine

K. Suzuki

2 Division of Hematology, Myeloma and AL Amyloidosis Center, Japanese Red Cross Medical Center

Y. Abe

3 Division of Hematology, Japanese Red Cross Medical Center, Tokyo

S. Ito

4 Division of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Iwate

K. Nishiwaki

5 Department of Clinical Oncology/Hematology, Kashiwa Hospital, The Jikei University School of Medicine, Tokyo

H. Handa

6 Division of Hematology, Department of Internal Medicine Medical Center, Gunma University Hospital, Gunma

T. Chou

7 Niigata Kenshin Plaza, General Incorporated Foundation, Health Medicine Prevention Association, Niigata

J. Soeda

8 Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Limited

I. Mori

8 Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Limited

T. Shinozaki

9 Department of Information and Computer Technology, Faculty of Engineering, Tokyo University of Science

N. Takezako

10 Division of Hematology, Japan Association for Development of Community Medicine, Nerima Hikarigaoka Hospital, Tokyo, Japan